

IP Law News

## **Amgen Loses Bid to Revive Antibody Patent in Regeneron Fight**

By Susan Decker

Oct. 13, 2020, 8:58 AM

---

Bloomberg Law News 2020-10-14T15:22:59831-04:00

Amgen Loses Bid to Revive Antibody Patent in Regeneron Fight

By Susan Decker2020-10-13T09:58:28543-04:00

Appeals court affirmed Patent Trial and Appeal Board decision that invalidated challenged claims of patent 8,679,487 owned by Amgen's Immunex.

- U.S. Court of Appeals for the Federal Circuit said PTAB was correct to invalidate the claims
- Since court said the patent was invalid, it declined to address Sanofi's arguments that a key inventor was excluded
- Patent is part of lawsuit Immunex lodged against Sanofi and Regeneron over their Dupixent eczema drug
- Patent covers human antibodies that block the actions of interleukin signaling molecules in the immune system
- Sanofi and Regeneron claimed Immunex sought to patent an "expansive universe of antibodies" including ones already known
- Docket link

To contact the reporter on this story:

Susan Decker in Washington at [sdecker1@bloomberg.net](mailto:sdecker1@bloomberg.net)

To contact the editors responsible for this story:

Jon Morgan at [jmorgan97@bloomberg.net](mailto:jmorgan97@bloomberg.net)

Brad Skillman

© 2020 Bloomberg L.P. All rights reserved. Used with permission.

© 2020 The Bureau of National Affairs, Inc. All Rights Reserved